Fosun Kite's FKC889 and Mingju Bio's JWCAR029 Designated as Breakthrough Therapy Candidates in China
Mar 24, 2022 16:00
CST Updated
16:00
Fosun Kairos
Developer of Tumor Immune Cell Therapy Technologies and Products
JW Therapeutics
CAR-T Product Developer
On March 24, the CDE website showed that Fosun Kite's FKC889 and Mingju Bio's JWCAR029 are proposed to be included in the breakthrough therapy category.
It is reported that the proposed indication for FKC889 is relapsed/refractory mantle cell lymphoma, and the proposed indication for JWCAR029 is adult relapsed/refractory mantle cell lymphoma treated with second-line or above therapy.
*Disclaimer: This article was written by an author who has settled in Sina Medicine News. The views expressed represent the personal opinions of the author and do not reflect the position of Sina Medicine News.